FDA — authorised 22 March 1996
- Marketing authorisation holder: GE HEALTHCARE
- Status: approved
🇺🇸 Visipaque 270 in United States
FDA authorised Visipaque 270 on 22 March 1996
Marketing authorisations
FDA — authorised 22 March 1996
- Application: NDA020351
- Marketing authorisation holder: GE HEALTHCARE
- Local brand name: VISIPAQUE 270
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 August 1997
- Application: NDA020808
- Marketing authorisation holder: GE HEALTHCARE
- Local brand name: VISIPAQUE 270
- Indication: INJECTABLE — INJECTION
- Status: approved
Visipaque 270 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Visipaque 270 approved in United States?
Yes. FDA authorised it on 22 March 1996; FDA authorised it on 22 March 1996; FDA authorised it on 29 August 1997.
Who is the marketing authorisation holder for Visipaque 270 in United States?
GE HEALTHCARE holds the US marketing authorisation.